For US healthcare professionals only.

Calculate your patient’s ELOCTATE® starting dose for routine prophylaxis, bleed control, or surgery1

2x weekly
Adjust the regimen based on patient response with dosing in the range of 25 to 65 IU/kg at 3- to 5-day intervals. In children <6 years of age, more frequent or higher doses up to 80 IU/kg may be required.
Estimated increment of factor VIII (% of normal) 50%
Estimated increment of factor VIII (% of normal) 100%
Factor VIII level required (IU/dL or % of normal) 40 – 60
 
Factor VIII level required (IU/dL or % of normal) 80 – 100
Dose range (IU/kg) 20 – 30
Dose range (IU/kg) 40 – 50
Frequency of dosing (hours) Repeat every 24–48 hours (12–24 hours for patients <6 years of age)
Frequency of dosing (hours) Repeat every 12–24 hours (8–24 hours for patients <6 years of age)
Duration of therapy Until the bleeding episode is resolved
Duration of therapy Until the bleeding episode is resolved (approximately 7–10 days)
 
Estimated increment of factor VIII
(% of normal)
50%100%
Factor VIII level required
(IU/dL or % of normal)
40 – 6080 – 100
Dose range (IU/kg)
20 – 3040 – 50
Frequency of dosing (hours)
Repeat every 24–48 hours (12–24 hours for patients
<6 years of age)
Repeat every 12–24 hours (8–24 hours for patients
<6 years of age)
Duration of therapy
Until the bleeding episode is resolvedUntil the bleeding episode is resolved
(approximately
7–10 days)
 
 
Factor VIII level required (IU/dL or % of normal) 50 – 80
 
Dose range (IU/kg) 25 – 40
 
Frequency of dosing (hours) Repeat every 24 hours (12–24 hours for patients <6 years of age)
 
Duration of therapy (days) At least 1 day, until healing is achieved
 
Factor VIII level required (IU/dL or % of normal) 80 – 120
 
Frequency of dosing (hours) Preoperative dose of 40–60 IU/kg followed by a repeat dose of 40–50 IU/kg after 8–24 hours (6–24 for patients <6 years of age) and then every 24 hours to maintain FVIII activity within the target range
 
Duration of therapy (days) Until adequate wound healing, then continue therapy for at least 7 days to maintain a factor VIII activity within the target range
 

Information in the above calculator is provided as a guide for dosing ELOCTATE for prophylaxis, the control of bleeding episodes, and perioperative management. Your independent medical consideration should be given to maintaining factor VIII activity at or above the target range.

*Minor and moderate bleed events: joint, superficial muscle/no neurovascular compromise (except iliopsoas), deep laceration and renal, superficial soft tissue, mucous membranes.1

Major bleed events: life- or limb-threatening hemorrhage, iliopsoas and deep muscle with neurovascular injury, retroperitoneum, intracranial, or gastrointestinal.1

Eligibility criteria apply. Those with federal and state government insurance, such as Medicare, Medicaid, or TRICARE®, are not eligible. Have your patients contact their MyELOCTATE™ Coordinator to see if they are eligible for any of these programs. Sanofi Genzyme reserves the right to modify or discontinue these programs at any time. TRICARE is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved.